Barrigel Rectal Spacer
Cross-source consensus on Barrigel Rectal Spacer from 1 sources and 7 claims.
1 sources · 7 claims
How it works
Benefits
Dosage & preparation
Evidence quality
Other
Highlighted claims
- The gel gradually resorbs over 1-3 years. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
- Rectal spacer gel is injected between the prostate and anterior rectal wall to increase separation and reduce rectal radiation dose. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
- Barrigel is a biodegradable hyaluronic acid gel inserted transperineally into Denonvilliers' fascia under ultrasound guidance. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
- At least 3 mL of Barrigel is inserted, with a goal of at least 1 cm separation from prostate base to apex. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
- Barrigel creates separation between the prostate and anterior rectal wall to protect rectal tissue from exit dose. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
- The timing and anesthesia for Barrigel insertion differ by treatment arm to avoid additional procedures and reduce burden. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
- Multiple studies have reported dosimetric and clinical benefits of rectal spacer gel, but randomized data are limited. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer